Cubist Pharmaceuticals, Inc. Reports Third Quarter 2007 Results: Total Revenues $79.8 Million; Net Product Revenues $76.3 Million, +52% vs. Q3 2006

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported results for the third quarter ended September 30, 2007. Total net product revenues for CUBICIN® (daptomycin for injection) increased 52% from the prior year, from $50.3 million in the third quarter of 2006 to $76.3 million in the third quarter of 2007. U.S. net sales of CUBICIN were $75.4 million. Total revenues for the third quarter of 2007 increased 58% over the third quarter of 2006 from $50.4 million in the third quarter of 2006 to $79.8 million in the third quarter of 2007.